Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Somatostatinoma 1Small Cell Lung Carcinoma 1Glioblastoma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 23Cisplatin 16pembrolizumab 6Fluorouracil 6pemigatinib 4Radiotherapy 3Oxaliplatin 3Leucovorin 3Drug Therapy 3infigratinib 2durvalumab 2ceritinib 2aldesleukin 2Radiosurgery 2Photochemotherapy 2Nivolumab 2Liver Transplantation 2Dexamethasone 2Cholangiopancreatography, Endoscopic Retrograde 2Carboplatin 2Capecitabine 2trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1spartalizumab 1seribantumab 1perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane) 1peginterferon alfa-2b 1pazopanib 1padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cholangiocarcinoma × irinotecan sucrosofate × Clear all
NCT05009953 2024-07-11

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Terminated
17 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡